Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma
AB rechallenge may be a safe and potentially effective treatment option for selected patients with unresectable HCC, even after discontinuation due to disease progression or adverse events.
Authors
- Hitomi Takada (ORCID: https://orcid.org/0000-0003-2101-0454)
- Shinya Maekawa (ORCID: https://orcid.org/0000-0002-5643-9472)
- Yoshihiko Tachi (ORCID: https://orcid.org/0000-0001-9799-2445)
- Shuya Matsuda
- Teiji Kuzuya (ORCID: https://orcid.org/0000-0002-2229-990X)
- Yoshiki Hirooka (ORCID: https://orcid.org/0000-0001-9639-7425)
- Atsunori Tsuchiya (ORCID: https://orcid.org/0000-0002-9279-5917)
- Hisanori Muto (ORCID: https://orcid.org/0000-0003-2121-2494)
- Leona Osawa (ORCID: https://orcid.org/0000-0002-4159-6467)
- Yasuyuki Komiyama
- Yuichiro Suzuki (ORCID: https://orcid.org/0000-0002-3070-7387)
- Nobuyuki Enomoto
- M. MURAOKA
- Mitsuaki Sato
Institutions
- Fujita Health University (JP)
- University of Yamanashi (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1111/hepr.70024
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32